Showing 5681-5690 of 10414 results for "".
- Topical Gel Bimiralisib Shows Promise for AK in Interim Resultshttps://practicaldermatology.com/news/Topical-Gel-Bimiralisib-Shows-Promise-AK-Interim-Results/2471537/Interim results from an ongoing Phase 2 clinical trial in actinic keratosis highlighted strong potential for the safety and efficacy of topical gel bimiralisib, a selective pan-PI3K/mTOR inhibitor, Torqur AG announced at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Fl
- Molluscum Contagiosum: Old Condition, Same Challengeshttps://practicaldermatology.com/news/molluscum-contagiosum-old-condition-same-challenges/2471528/Molluscum contagiosum has been studied and treated for almost two centuries, and while modern therapies are helping patients obtain better outcomes, some aspects of managing and treating the disease remain challenging At the 2025 American Academy of Dermatology (AAD) Annual Meeting, Dr. Ad
- IPC Comorbidities Symposium Covers Depression, Obesity, and Morehttps://practicaldermatology.com/news/IPC-Comorbidities-Symposium-Covers-Depression-Obesity-More/2471517/Comorbidities of psoriasis were the focus of the International Psoriasis Council’s meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “Syposium: Preventing Comorbig Disease in Psoriasis” started with presentations on depression and card
- Analysis: Biosimilars Show Comparable Effectiveness to Humira in Psoriasishttps://practicaldermatology.com/news/analysis-biosimilars-show-comparable-effectiveness-to-humira-in-psoriasis/2471496/Adalimumab biosimilars Amjevita and Imraldi showed similar effectiveness to Humira for the treatment of psoriasis in both new users and patients switching from Humira, according to an analysis of the British Association of Dermatologists Biologics and Immunomodulato
- TSC Reduces Tretinoin-Induced Skin Irritation: Pilot Studyhttps://practicaldermatology.com/news/tsc-reduces-tretinoin-induced-skin-irritation-pilot-study/2471409/A recent pilot study has shown that tetramethylhexadecenyl succinoyl cysteine (TSC) significantly reduces erythema and dryness caused by tretinoin application. These findings may offer a novel approach to minimizing the common adverse effects of tretinoin, potential
- Phase 1 Trial Shows Safety and Dosing Potential for Combo IL-13 Therapy for ADhttps://practicaldermatology.com/news/phase-1-trial-shows-safety-and-dosing-potential-for-combo-il-13-therapy-for-ad/2471401/Apogee Therapeutics has reported positive interim results from a Phase 1 trial evaluating APG990, a subcutaneous, extended half-life monoclonal antibody targeting OX40L, for inflammatory and immunological conditions such as atopic dermatitis (AD), according to a pre
- Study: AI Model Improves Hair Growth, Texturehttps://practicaldermatology.com/news/ai-model-improves-hair-growth-texture/2471394/An artificial intelligence (AI)-driven platform for customizing hair loss treatments significantly improved hair growth, scalp health, and hair texture in a 24-week study involving women with self-reported hair thinning. The st
- Sanofi to Present Data on Dupilumab for BP, AD, CSU, PN, Plus Amlitelimabhttps://practicaldermatology.com/news/Sanofi-Present-Data-Dupilumab-BP-AD-CSU-PN-Plus-Amlitelimab/2471384/Sanofi will present 26 abstracts, including one late-breaking and five additional oral presentations, across approved and investigational medicines at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, from March 7-11. Presentations in partnership with Regeneron
- Pilot Study Suggests Selumetinib's Potential for Cutaneous Neurofibromashttps://practicaldermatology.com/news/pilot-study-suggests-selumetinibs-potential-for-cutaneous-neurofibromas/2471373/A new nonrandomized pilot trial suggested the MEK inhibitor selumetinib was associated with a reduction in the size of cutaneous neurofibromas in patients with Neurofibromatosis Type 1 (NF1). These study, published as a brief rep
- FDA Accepts sNDA for Roflumilast Cream for AD Patients Ages 2-5https://practicaldermatology.com/news/FDA-Accepts-sNDA-Roflumilast-Cream-AD-Patients-Ages-2-5/2471351/The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%, for the topical treatment of mild to moderate atopic dermatitis (AD) in children 2 to 5 years old, Arcutis Biotherapeutics, Inc. announced. The FDA has se